Lyell Immunopharma Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Lyell Immunopharma stock has a consensus rating of "Buy" and an average price target of $37.17. The average 1-year stock price forecast is 206.68% higher than the current stock price, while the lowest is $12 (-0.99%) and the highest is $49 (+304.29%).

Price Target: $37.17 (+206.68%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$12	$37.17	$41.5	$49
Change	-0.99%	+206.68%	+242.41%	+304.29%

Analyst Ratings

The average analyst rating for Lyell Immunopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	2	2	2	3	3	3
Buy	0	0	1	2	2	2
Hold	0	0	0	0	0	0
Sell	1	1	1	1	0	1
Strong Sell	0	0	0	0	0	0
Total	3	3	4	6	5	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gil Blum Needham	Needham	Buy Maintains $44	Buy	Maintains	$44	+263.04%	Jun 8, 2026
Jason Zemansky Bank of America Securities	Bank of America Securities	Sell Reiterates $12	Sell	Reiterates	$12	-0.99%	Jun 3, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $45	Buy	Reiterates	$45	+271.29%	Jun 3, 2026
Jack Allen Robert W. Baird	Robert W. Baird	Buy Initiates $49	Buy	Initiates	$49	+304.29%	Apr 30, 2026
Reni Benjamin Citizens JMP	Citizens JMP	Buy Initiates $34	Buy	Initiates	$34	+180.53%	Mar 9, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

13.67K

from 36.00K

-62.03%

from 36.00K

Revenue Next Year

7.86M

from 13.67K

57,430.87%

from 13.67K

EPS This Year

-5.70

from -

EPS Next Year

-3.35

from -5.70

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	10.65M	84.68M	130.00K	61.00K	36.00K	13.67K
Revenue Growth	37.31%	695.15%	-99.85%	-53.08%	-40.98%	-62.03%
Operating Income	-213.57M	-186.96M	-245.50M	-218.93M	-198.29M	-204.66M
Net Income	-250.22M	-183.12M	-234.63M	-342.99M	-274.45M	-181.35M
EPS	-	-	-	-	-	-5.70
Free Cash Flow	-129.82M	-53.90M	-90.36M	-67.56M	-81.47M	-61.48M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	46,000
Avg	13,670
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	27.8%
Avg	-62.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-5.70
Avg	-5.70
Low	-5.70

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-